Artivion (AORT) CEO Mackin exercises 30,921 stock options and sells shares

Rhea-AI Filing Summary

Artivion, Inc. reported an insider stock transaction by its President & CEO, James P. Mackin. On December 3, 2025, he exercised stock options to acquire 30,921 shares of Artivion common stock at an exercise price of $29.62 per share, then sold the same 30,921 shares in the open market at a weighted average price of approximately $45.461 per share.

The option exercise and sale were conducted under a Rule 10b5-1 trading plan adopted on September 2, 2025. After these transactions, he directly owns 800,993 shares of Artivion common stock. The reported stock option, originally granted on March 5, 2020 with an expiration date of March 5, 2026, is now fully exercised and shows 0 options remaining.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mackin James P

(Last) (First) (Middle)

ARTIVION, INC.

1655 ROBERTS BLVD, NW

(Street)

KENNESAW GA 30144

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ARTIVION, INC. [ AORT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & CEO

3. Date of Earliest Transaction (Month/Day/Year)
12/03/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/03/2025		M		30,921(1)	A	$29.62	831,914	D
Common Stock	12/03/2025		S		30,921(1)	D	$45.461(2)	800,993	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (Right to buy)	$29.62	12/03/2025		M			30,921	03/05/2020	03/05/2026(3)	Common Stock	30,921	$0	0	D

Explanation of Responses:

1. The sale reported on this form was effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 2, 2025.

2. Reflects weighted average price. Range of prices were between $45.09 to $45.91. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

3. Stock option vests 33 1/3% per year beginning on the first anniversary of the grant date. The first exercisable date was March 5, 2020.

Remarks:

	/s/ James P. Mackin	12/04/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Artivion (AORT) disclose for James P. Mackin?

Artivion disclosed that its President & CEO, James P. Mackin, exercised stock options for 30,921 shares of common stock at $29.62 per share on December 3, 2025 and sold the same 30,921 shares at a weighted average price of about $45.461 per share.

How many Artivion (AORT) shares does the CEO own after this Form 4 transaction?

Following the reported option exercise and stock sale, President & CEO James P. Mackin directly owns 800,993 shares of Artivion, Inc. common stock.

Was the Artivion (AORT) CEO’s stock sale under a Rule 10b5-1 trading plan?

Yes. The filing states that the sale was effected pursuant to a Rule 10b5-1 trading plan adopted by James P. Mackin on September 2, 2025, which is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

What stock option details were reported in this Artivion (AORT) Form 4?

The Form 4 reports a stock option (right to buy) for 30,921 shares with an exercise price of $29.62 per share, granted on March 5, 2020 and expiring on March 5, 2026. The option vested 33 1/3% per year beginning on the first anniversary of the grant date and is now fully exercised, leaving 0 options beneficially owned.

What was the price range for the Artivion (AORT) CEO stock sale on December 3, 2025?

The filing notes that the reported sale price of $45.461 per share reflects a weighted average price. The actual sale prices ranged between $45.09 and $45.91 per share, and full breakdowns by price level are available upon request.

What is the relationship of the reporting person to Artivion (AORT)?

The reporting person, James P. Mackin, is identified as an officer of Artivion, serving as its President & CEO, and the Form 4 is filed as a single reporting person filing.